Genmab — December 2014
-
DLBLC studiet præsenteres. Men det er altså et fejlet studie, så ikke meget at hente derfra nok
-
-
Arzerra falder fuldtændig igenem overfor Rituxan (I Rituxan relapsed patienter) det er altså ikke godt.
Der er bedre responser og bedr PFS i Rituxan armen. Kun lidt bedre OS i Ofa armen -
-
Kursen fortsætter bare. 326 nu
-
nogen skal jo sælge
Jyske og sydbank kan jo ikke gøre det hele tiden :)Så mange aktier har FF ikke
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind